-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Salivary Gland Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Salivary Gland Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed death-ligand...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sodium Nitrite in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sodium Nitrite in Cystic Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sodium nitrite in Cystic Fibrosis Drug Details: Sodium nitrite (RESP301)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 3K3A-APC in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 3K3A-APC in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.3K3A-APC in Amyotrophic Lateral Sclerosis Drug Details:3K3A-APC is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UBTT-170 in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UBTT-170 in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UBTT-170 in Osteosarcoma Drug Details: UBTT-170 is under development for the treatment...
-
Product Insights
Umoja BioPharma – Louisville Development and Clinical Manufacturing Facility – Colorado
Equip yourself with the essential tools needed to make informed and profitable decisions with our Umoja BioPharma - Louisville Development and Clinical Manufacturing Facility - Colorado report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – UBTT-170
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry UBTT-170 Drug Details UBTT-170 is under development for the treatment of pediatric osteosarcoma. It...
-
Product Insights
Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Osteosarcoma Drugs in Development market research report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research...